文献速递神经肿瘤神经重症

非腺瘤性鞍区及鞍旁病变术前术后垂体激素替代需求:鞍区侵占评分的重要性

Pre- and postoperative need for pituitary hormone replacement in non-adenomatous sellar and parasellar lesions: importance of the sellar encroachment score.
PubMed 文献 · Acta Neurochir (Wien) · 2020-06-06

多因素分析显示鞍区侵占评分是术前(OR=2.6,95%CI=1.2-5.5,p=0.01)和术后新发垂体激素替代需求(OR=4.1,95%CI=1.7-10.1,p=0.002)的唯一预测因素。

要点

  • 鞍区侵占评分可预测非腺瘤性鞍区病变术前及术后垂体激素替代需求。
  • 74%患者术前无需垂体激素替代,术后35%患者需求增加。
  • 鞍区侵占评分越高,术前及术后新发垂体激素替代风险越高。

核心结论

  • 相当比例的非腺瘤性鞍区/鞍旁病变患者需要垂体激素替代,且术后可能加重。
  • 鞍区侵占程度可预测术前及术后垂体激素替代状态。

研究设计与样本

  • 单中心回顾性综述,纳入组织学确诊的非腺瘤性鞍区/鞍旁病变成人患者,随访≥3个月或至术后放疗。
  • 垂体功能障碍定义为需要激素替代;鞍区侵占评分(0-6分)为冠状位和矢状位鞍区影像学侵占三分之一的评分之和。
  • 采用二元逻辑回归多因素分析确定与垂体激素替代相关的因素。

主要发现

  • 手术方式:经蝶53%,经颅36%,联合11%。
  • 最常见组织学类型为脑膜瘤(n=33,28%)和颅咽管瘤(n=20,17%)。
  • 鞍区侵占评分中位数为6分(范围0-6)。
  • 术前86例(74%)无需垂体激素替代;术后41例(35%)患者垂体激素需求增加。
  • 多因素分析中,鞍区侵占评分是术前(OR=2.6,95%CI=1.2-5.5,p=0.01)和术后新发垂体激素替代(OR=4.1,95%CI=1.7-10.1,p=0.002)的唯一预测因素。

关键数值与推荐

  • 鞍区侵占评分(0-6分):冠状位和矢状位鞍区影像学侵占三分之一的评分之和。
  • 垂体功能障碍定义:需要垂体激素替代。
  • 术前垂体激素替代预测:鞍区侵占评分OR=2.6(95%CI=1.2-5.5,p=0.01)。
  • 术后新发垂体激素替代预测:鞍区侵占评分OR=4.1(95%CI=1.7-10.1,p=0.002)。

临床怎么用

  • 对非腺瘤性鞍区/鞍旁病变患者,可采用鞍区侵占评分评估术前及术后垂体激素替代风险。
  • 鞍区侵占评分较高的患者应加强围手术期内分泌功能监测与激素替代管理。

局限性

  • 单中心回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pre-/postoperative pituitary endocrine deficiencies in patients with sellar/parasellar non-adenomatous lesions are poorly described and studies have not considered the effect of sellar invasion on endocrine outcome. The aim of this study was to relate the need for pituitary hormone replacement pre-/postoperatively, with sellar invasion, in non-adenomatous sellar/parasellar lesions. METHODS: Single-centre review of adults with histologically confirmed non-adenomatous sellar/parasellar lesion and follow-up ≥ 3 months or until postop radiotherapy. Pituitary dysfunction was defined by hormone replacement. The sellar encroachment score (0-6) was calculated as the sum of the thirds of radiological encroachment into the sellar region in the coronal and sagittal planes. Multivariate analysis with binary logistic regression was used to determine factors associated with pituitary hormone replacement. RESULTS: One hundred and seventeen patients were included with a median age of 49 years (range 16-84 years) and median follow-up of 13 months. Surgery was trans-sphenoidal (53%), trans-cranial (36%) or a combination (11%). The commonest histology types were meningioma (n = 33, 28%) and craniopharyngioma (n = 20, 17%). The median sellar encroachment score was 6 (range 0-6). Most (n = 86, 74%) did not require pituitary hormone replacement preoperatively. The need for pituitary hormones increased after surgery in 41 (35%) patients. In multivariate analysis, the sellar encroachment score was the only factor predictive of pre- (OR = 2.6, 95% CI = 1.2-5.5; p = 0.01) and postoperative risk of new pituitary hormone replacement (OR = 4.1, 95% CI = 1.7-10.1, p = 0.002). CONCLUSION: A significant proportion of these patients present with need for pituitary hormone replacement that may worsen postoperatively. The degree of sellar encroachment is predictive of pituitary hormone replacement status pre-/postoperatively.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Waqar M, Rampersad S, Bennett D, et al. Pre- and postoperative need for pituitary hormone replacement in non-adenomatous sellar and parasellar lesions: importance of the sellar encroachment score. Acta Neurochir (Wien). 2020. PMID: 32506330. doi:10.1007/s00701-020-04440-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。